

Bederra Corporation Subsidiary Receives Approval From Major Insurance Carrier

Tuesday April 15, 10:30 am ET

HOUSTON, TX--(MARKET WIRE)--Apr 15, 2008 -- Bederra Corporation (Other OTC:[BDRR.PK - News](#)), a medical imaging and diagnostic Company, is pleased to announce that its subsidiary Company, Lumar Imaging, Inc. has received approval to provide imaging services to the Medicare and Medicaid covered lives of Amerigroup Corporation.

AMERIGROUP Corporation, headquartered in Virginia Beach, Virginia, is a multi-state managed health care company focused on serving people who receive health care benefits through state-sponsored programs. From Medicaid, Temporary Assistance for Needy Families (TANF) and State Children's Health Insurance Programs (SCHIP) to Supplemental Security Income (SSI), Long Term Care and Medicare coverage, they help people of all ages get the care they need and the respect they deserve. Through its many AMERIGROUP Community Care subsidiaries, they currently help more than 1.7 million low-income Americans throughout the nation. The company operates in Florida, Georgia, Maryland, New Jersey, New York, Ohio, South Carolina, Tennessee, Texas, Virginia and the District of Columbia.

About Bederra Corporation.

Bederra Corporation, which wholly owns Diagnos, Inc. and Lumar Imaging, Inc., provides multiple modality diagnostic medical imaging services to the greater Houston area and world famous Texas medical center. The company's current strategy is to grow its current operations and seek out additional acquisitions that will complement its core operations.

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.